Nuvation Bio (NUVB) Receives a Buy from RBC Capital

Nuvation Bio (NUVB) Gets a Buy from TD Cowen

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Strategic Acquisition Bolsters Nuvation Bio’s Growth Potential and Pipeline Prospects

Strategic Acquisition Bolsters Nuvation Bio’s Growth Potential and Pipeline Prospects

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know

Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know

Nuvation Bio: A Strong Buy on Robust Financials and Promising Pipeline Catalysts